Treace Medical preliminary Q4 rev ~$68.6M, FY2024 ~$209.2M, up 12% YoY

TREACE MEDICAL CONCEPTS, INC.

2024-FY EPS reported -$0.90 revenue$209,357,000

Preliminary Q4 revenue $68.4M-$68.8M, ~10% increase at midpoint vs Q4 2023.
Full-year 2024 revenue $209.0M-$209.4M, ~12% growth at midpoint, in line with $204M-$211M guidance.
Added ~280 active surgeons in 2024; total ~3,135 active surgeons (+10% YoY), ~31% of US bunion surgeon market.
2025 financial guidance to be provided during Q4 2024 earnings call on Feb 27, 2025.
Management to present at J.P. Morgan Healthcare Conference on Jan 14, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.